pembrolizumab
merck
updated data from keynote-224 study #wcgic2022 pembrolizumab in 2nd line #hcc orr 18%, mpfs 4.9, mos 13.2 keynote-224, -240 and -394 confirm activity of pembro in subgroup of patients with durable benefit we need biomarker #livertwitter 
Physician-scientist, focussed on translational research in hepatobiliary cancer and precision medicine